IL1A and breast carcinoma: Whereas, in breast cancer blocking IL-1 activity with anakinra or the IL-1β specific antibody, canakinumab, reduced breast cancer metastasis by inhibiting epithelial to mesenchymal transition and preventing metastatic outgrowth of disseminated tumour cells via inhibition of wnt signalling pathways [60–62].